about
JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entitiesEarly-onset stroke and vasculopathy associated with mutations in ADA2Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.Active thrombopoiesis is associated with worse severity and activity of chronic GVHD.Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome.Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixaforNonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiencyGATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia.Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutationRole of microRNAs from monoclonal gammopathy of undetermined significance to multiple myelomaPrimary diffuse large B-cell lymphoma of the spleen with coincident serous retinal detachments responsive to corticosteroids.Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.Measurement of the absolute immature platelet number reflects marrow production and is not impacted by platelet transfusionLong-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.Effect of viral decontamination measures on Wright-stained blood smears.Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trialHairy cell leukemia coexistent with chronic lymphocytic leukemiaNup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphomaCardiac magnetic resonance appearance of myocarditis caused by high dose IL-2: similarities to community-acquired myocarditisMastocytosis: the new differential diagnosis of CD30-positive neoplasmsDonor-derived MDS/AML in families with germline GATA2 mutationInherited thrombocytopenia and platelet disorders with germline predisposition to myeloid neoplasiaSerum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance
P50
Q28082598-C01A09FA-91F9-4935-98E3-CA2133BBB35DQ30410263-81E4738F-84FB-4E0E-B051-53BA3296AC4DQ33162197-21C00F11-6B0D-4F3D-8322-59068A3B502CQ33408944-F6E7F8FE-FC05-46E3-AC58-234B23F89B54Q34147360-84D55406-78AC-44A3-A7FF-AAAF6D51DC4EQ34192317-3C691CC1-5123-45F6-B63B-441EE17F5BF2Q34289493-D2048AC9-E2E1-48EF-A96A-20087995B9E8Q34387911-D09B8890-2541-4D61-AF60-83B318A3D126Q34392449-2EF4142A-81B9-4CB1-A701-98E5ADC4265CQ34403975-1666DF48-428D-4DEB-977C-1B373E534EB4Q34619834-1D7392A7-8F40-46E4-AB18-A7D3A520E01CQ34802461-3E576669-3F1A-41D1-B0FA-206FC143E6EBQ35266306-D98970C4-CCA3-4BC1-BA4D-09DD7095CF9FQ35876956-F8AF1BE3-1963-4032-BDA4-5841984F6852Q35910526-B5949626-95FE-44FA-9F56-D93B5BF907B6Q35945515-3F5246CF-1E06-4616-84DA-A73AA7294CAEQ36285066-9E31E519-E739-45FA-A28A-692D437F2807Q36527532-1D67E08A-65AA-4578-94F1-152AD140BCB9Q36883869-550DC8E6-A989-4608-B2AF-5E142751E77EQ36910794-18C31626-8D85-4525-8CD9-5FE6A195CA0BQ37564756-6187F228-D268-4B5F-91F0-BCF8609D2C48Q39868726-4C05C85B-EECA-4EC2-BDAC-273CF4EA4F43Q41553732-40914A18-931B-46A7-ADCA-E23E912F292AQ43156023-9DD63E21-195F-4429-9CA6-22588D6CCC7AQ56645266-FF176482-2BFC-4227-9B73-88055D8F04E4Q64091875-2DECB3D1-A793-4355-B8FB-F3EEF7658E6EQ74355519-BF6261E3-3C52-4716-91BF-CEE4EA724CD7Q80476118-263E0DF0-AD8E-4FE7-8F3A-E0C3A56F2F47Q83273756-A8F94932-A81E-4A6F-B075-21EB356DB328Q83777656-1AFDCE77-9220-4D9C-A55B-6AF72FF2DBDCQ91553288-26BCB101-6937-403B-BB1A-2CBCEB144B59Q91874880-C73BCC5D-03C5-4B1F-87DF-BC85E91525C2Q91886335-871DB4F7-05D3-4CE9-B0DA-65CA6F63DD33
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Katherine R. Calvo
@ast
Katherine R. Calvo
@en
Katherine R. Calvo
@es
Katherine R. Calvo
@nl
Katherine R. Calvo
@sl
type
label
Katherine R. Calvo
@ast
Katherine R. Calvo
@en
Katherine R. Calvo
@es
Katherine R. Calvo
@nl
Katherine R. Calvo
@sl
prefLabel
Katherine R. Calvo
@ast
Katherine R. Calvo
@en
Katherine R. Calvo
@es
Katherine R. Calvo
@nl
Katherine R. Calvo
@sl
P106
P1153
6603777643
P21
P31
P496
0000-0002-0771-4191